Table 1

Baseline characteristics of all randomized participants

Gla-300 (n = 404)Gla-100 (n = 403)
Age (years)60.1 (8.5)59.8 (8.7)
Sex (male), n (%)217 (53.7)210 (52.1)
Ethnic group, n (%)
 Caucasian371 (91.8)374 (92.8)
 Black26 (6.4)21 (5.2)
 Asian/Oriental6 (1.5)5 (1.2)
 Other1 (0.2)3 (0.7)
Body weight (kg)106.2 (21.5)106.4 (20.0)
BMI (kg/m2)36.6 (6.8)36.6 (6.1)
Duration of diabetes (years)15.6 (7.2)16.1 (7.8)
Duration of basal insulin treatment (years)6.7 (4.7)6.5 (4.8)
Basal insulin dose
 (units/kg/day)0.67 (0.26)0.67 (0.24)
 (units/day)70.0 (30.4)70.3 (28.5)
Mealtime insulin dose
 (units/kg/day)0.54 (0.34)0.54 (0.32)
 (units/day)57.1 (36.5)58.4 (37.9)
Total insulin dose
 (units/kg/day)1.19 (0.48)1.20 (0.45)
 (units/day)126.3 (56.7)128.0 (56.1)
Prior use of insulin glargine, n (%)373 (92.3)369 (91.6)
Prior use of metformin, n (%)227 (56.2)236 (58.6)
FPG
 (mmol/L)8.8 (2.9)8.9 (2.9)
 (mg/dL)158.3 (51.8)160.7 (52.8)
HbA1c
 (%)8.15 (0.78)8.16 (0.77)
 (mmol/mol)65.6 (8.5)65.7 (8.4)
  • Data are presented as mean (SD), unless otherwise indicated.